Search Results - "Hoering, A"

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents by USMANI, Saad Z, HEUCK, Christoph, VAN RHEE, Frits, CROWLEY, John, BARLOGIE, Bart, MITCHELL, Alan, SZYMONIFKA, Jackie, NAIR, Bijay, HOERING, Antje, ALSAYED, Yazan, WAHEED, Sarah, HAIDER, Sajjad, RESTREPO, Alejandro

“…Extramedullary disease is an uncommon manifestation in multiple myeloma and can either accompany newly diagnosed disease or develop with disease progression or…”
Get full text

In Situ Sensor Technology for Simultaneous Spectrophotometric Measurements of Seawater Total Dissolved Inorganic Carbon and pH by Wang, Zhaohui Aleck, Sonnichsen, Frederick N, Bradley, Albert M, Hoering, Katherine A, Lanagan, Thomas M, Chu, Sophie N, Hammar, Terence R, Camilli, Richard

“…A new, in situ sensing system, Channelized Optical System (CHANOS), was recently developed to make high-resolution, simultaneous measurements of total…”
Get full text

Automated Spectrophotometric Analyzer for Rapid Single-Point Titration of Seawater Total Alkalinity by Li, Quanlong, Wang, Fengzhen, Wang, Zhaohui Aleck, Yuan, Dongxing, Dai, Minhan, Chen, Jinshun, Dai, Junwei, Hoering, Katherine A

“…An automated analyzer was developed to achieve fast, precise, and accurate measurements of seawater total alkalinity (A T) based on single-point titration and…”
Get full text

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? by Usmani, S Z, Crowley, J, Hoering, A, Mitchell, A, Waheed, S, Nair, B, AlSayed, Y, vanRhee, F, Barlogie, B

“…The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of…”
Get full text

Inorganic carbon speciation and fluxes in the Congo River by Wang, Zhaohui Aleck, Bienvenu, Dinga Jean, Mann, Paul J., Hoering, Katherine A., Poulsen, John R., Spencer, Robert G. M., Holmes, Robert M.

“…Seasonal variations in inorganic carbon chemistry and associated fluxes from the Congo River were investigated at Brazzaville‐Kinshasa. Small seasonal…”
Get full text

Clinical value of molecular subtyping multiple myeloma using gene expression profiling by Weinhold, N, Heuck, C J, Rosenthal, A, Thanendrarajan, S, Stein, C K, Van Rhee, F, Zangari, M, Hoering, A, Tian, E, Davies, F E, Barlogie, B, Morgan, G J

“…Using a data set of 1217 patients with multiple myeloma enrolled in Total Therapies, we have examined the impact of novel therapies on molecular and risk…”
Get full text

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma by Heuck, C J, Qu, P, van Rhee, F, Waheed, S, Usmani, S Z, Epstein, J, Zhang, Q, Edmondson, R, Hoering, A, Crowley, J, Barlogie, B

Get full text

Renal insufficiency retains adverse prognostic implications despite renal function improvement following Total Therapy for newly diagnosed multiple myeloma by Khan, R, Apewokin, S, Grazziutti, M, Yaccoby, S, Epstein, J, van Rhee, F, Rosenthal, A, Waheed, S, Usmani, S, Atrash, S, Kumar, S, Hoering, A, Crowley, J, Shaughnessy, J D, Barlogie, B

“…Renal insufficiency (RI) is a frequent complication of multiple myeloma (MM) with negative consequences for patient survival. The improved clinical outcome…”
Get full text

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma by Pineda-Roman, M, Zangari, M, van Rhee, F, Anaissie, E, Szymonifka, J, Hoering, A, Petty, N, Crowley, J, Shaughnessy, J, Epstein, J, Barlogie, B

“…Bortezomib (V) was combined with thalidomide (T) and dexamethasone (D) in a phase I/II trial to determine dose-limiting toxicities (DLT's) and clinical…”
Get full text

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols by Usmani, S Z, Nair, B, Qu, P, Hansen, E, Zhang, Q, Petty, N, Waheed, S, Shaughnessy, J D, Alsayed, Y, Heuck, C J, van Rhee, F, Milner, T, Hoering, A, Szymonifka, J, Sexton, R, Sawyer, J, Singh, Z, Crowley, J, Barlogie, B

“…To determine whether primary plasma cell leukemia (PPCL) remains a high-risk multiple myeloma feature in the context of contemporary therapy and…”
Get full text

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal by Usmani, S Z, Hoering, A

Get full text

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy by GARG, Tarun K, SZMANIA, Susann M, SUVA, Larry J, STORRIE, Brian, TRICOT, Guido, CAMPANA, Dario, SHAUGHNESSY, John D, NAIR, Bijay P, BELLAMY, William T, EPSTEIN, Joshua, BARLOGIE, Bart, RHEE, Frits Van, KHAN, Junaid A, HOERING, Antje, MALBROUGH, Paul A, MORENO-BOST, Amberly, GREENWAY, Amy D, LINGO, Joshuah D, XIN LI, YACCOBY, Shmuel

“…Patients with gene expression profiling-defined high-risk myeloma in relapse have poor outcomes with current therapies. We tested whether natural killer cells…”
Get full text

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE by Rhee, F., Rosenthal, A., Kanhai, K., Martin, R., Nishimura, K., Hoering, A., Fajgenbaum, D.

Get full text

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma by Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F

“…Multiple myeloma (MM) is a heterogeneous disease with high-risk patients progressing rapidly despite treatment. Various definitions of high-risk MM are used…”
Get full text

P965: FOLLOW‐UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG‐1211) by Usmani, S., Hoering, A., Ailawadhi, S., Sexton, R., Lipe, B., Valent, J., Rosenzweig, M., Zonder, J., Dhodapkar, M., Callander, N., Zimmerman, T., Voorhees, P., Durie, B., Rajkumar, S. V., Richardson, P., Orlowski, R.

Get full text

The biogeochemistry of carbon across a gradient of streams and rivers within the Congo Basin by Mann, P. J., Spencer, R. G. M., Dinga, B. J., Poulsen, J. R., Hernes, P. J., Fiske, G., Salter, M. E., Wang, Z. A., Hoering, K. A., Six, J., Holmes, R. M.

“…Dissolved organic carbon (DOC) and inorganic carbon (DIC, pCO2), lignin biomarkers, and theoptical properties of dissolved organic matter (DOM) were measured…”
Get full text

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211 by Usmani, S Z, Sexton, R, Ailawadhi, S, Shah, J J, Valent, J, Rosenzweig, M, Lipe, B, Zonder, J A, Fredette, S, Durie, B, Hoering, A, Bartlett, B, Orlowski, R Z

Get full text

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma by Usmani, S Z, Zhang, Q, Stratton, K, Qu, P, Yaccoby, S, Hansen, E, Steward, D, Panozzo, S, Petty, N, Hoering, A, Waheed, S, Van Rhee, F, Crowley, J, Barlogie, B

Get full text

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115 by Sanchorawala, V, Hoering, A, Seldin, D C, Finn, K T, Fennessey, S A, Sexton, R, Mattar, B, Safah, H F, Holmberg, L A, Dean, R M, Orlowski, R Z, Barlogie, B

“…We designed a trial using two sequential cycles of modified high-dose melphalan at 100 mg/m 2 and autologous SCT (mHDM/SCT) in AL amyloidosis (light-chain…”
Get full text

Tracing river chemistry in space and time: Dissolved inorganic constituents of the Fraser River, Canada by Voss, Britta M., Peucker-Ehrenbrink, Bernhard, Eglinton, Timothy I., Fiske, Gregory, Wang, Zhaohui Aleck, Hoering, Katherine A., Montluçon, Daniel B., LeCroy, Chase, Pal, Sharmila, Marsh, Steven, Gillies, Sharon L., Janmaat, Alida, Bennett, Michelle, Downey, Bryce, Fanslau, Jenna, Fraser, Helena, Macklam-Harron, Garrett, Martinec, Michelle, Wiebe, Brayden

“…The Fraser River basin in southwestern Canada bears unique geologic and climatic features which make it an ideal setting for investigating the origins,…”
Get full text